Monsanto Issues, Repays Debt

Zacks

Monsanto Company (MON) resorted to repaying its maturing debt by floating fresh senior notes having a 10- and 30-year maturity period.  The issue will be settled on July 12, 2012.

Senior unsecured notes worth $500 million have been issued precisely in two equal parts. The first lot consists of $250 million aggregate principal amount of 2.2% senior notes due on July 15, 2022. Yield to maturity on these notes is 2.213% and have been offered at 99.884% to the public. Interest will be paid semi-annually on these beginning January 15, 2013.

The second lot consists of another $250 million aggregate principal amount of 3.6% senior notes, due to mature on July 15, 2042. These notes will yield 3.608% on maturity and have been offered at 99.854%. Interest will be paid semi-annually on these beginning January 15, 2013.

The proceeds from the issuance will be used to repay $486 million of 7 3/8% senior notes maturing on August 15, 2012. Monsanto currently holds A1 (Stable) Rating issued by Moody’s, A+ (Stable) by S&P, and A+ (Stable) by Fitch credit rating agencies.   

We believe the debt issuance-repayment arrangement made will work in favour of the company and help it retain its solid balance sheet position. Fiscal third quarter 2012 ending, the company had approximately $1,538 million of long-term debt, net of current portions as against a whopping $1,716 million of cash and cash equivalents balance.

Monsanto’s biotechnology research and innovations position it as a market leader above its peers, such as Syngenta AG (SYT) and The Dow Chemical Company (DOW).

The current Zacks Consensus Estimate for the fiscal fourth quarter 2012 is a loss of 44 cents, representing a year-over-year decline of 98.70%. Estimates for the fiscal years 2012 and 2013 are $3.70 and $4.30, reflecting annual growth of 25.12% and 16.06%, respectively.

Monsanto has a Zacks #1 Rank, which translates into a short-term Strong Buy rating (1-3 months).

Read the Full Research Report on DOW

Read the Full Research Report on SYT

Read the Full Research Report on MON

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)